Its lead stem cell therapeutic candidate is a therapy for the treatment of patients left disabled by a stroke.

The company's principal strategy is to gain clinical validation for its cell therapy programs via clinical trials in well-regulated territories.

ReNeuron expects to out-license to commercial development partners at the appropriate points in different candidates' development, and works closely with a number of key academic and industrial partners while retaining control over financial resources.